This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
About us
Our story
Cerulea Clinical Trials’ state-of-the-art facilities and experienced team deliver innovation and excellence in ophthalmic clinical trials.
Introducing Cerulea Clinical Trials
Cerulea Clinical Trials delivers ophthalmic clinical trials for Australian and international biopharmaceutical and medtech companies – and is the home of investigator-initiated studies for the Centre for Eye Research Australia (CERA).
We are a fully owned, not-for-profit subsidiary of CERA and share its vision of a world free from vision loss and blindness.
Our ambition is for Cerulea to be a world-recognised and trusted partner in clinical trials, playing a pivotal role in translating research discoveries expertly and efficiently from bench to bedside.
We are committed to delivering the best clinical trial experience for participants, clinicians, and sponsors for discoveries that will become therapies on world markets.
Our work and specialist capabilities in trailing advanced therapeutics such as gene and cell therapies, will provide Australians living with vision loss and blindness early access to emerging new treatments.
We also have a remit to partner with Melbourne’s flourishing biotech and medtech ecosystem – providing opportunities for local scientists and inventors to trial new eye treatments and devices in Australia.
Our purpose-built ophthalmic trials unit, located in the Royal Victorian Eye and Ear Hospital, and was built with the support for a $10million investment from Breakthrough Victoria, an independent organisation that manages an innovation investment fund established by the Victorian Government.
We are registered with the Australian Charities and Not-for-Profits Commission and governed by a separate Board which includes representatives from CERA, Breakthrough Victoria and independent directors with expertise in global clinical trials and translational research.
Our revenue is invested back into vision research at CERA, as well as investing in creating a better experience for trial participants, clinicians and sponsors, and into new equipment and services that can be utilized by trial sponsors and clinician researchers, to support investigator-initiated clinical research and fund vital lab-based discovery research.
Working together, we will put new treatments in sight for people living with vision loss and blindness.
Cerulea Clinical Trials delivers ophthalmic clinical trials for Australian and international biopharmaceutical and medtech companies – and is the home of investigator-initiated studies for the Centre for Eye Research Australia (CERA).
We are a fully owned, not-for-profit subsidiary of CERA and share its vision of a world free from vision loss and blindness.
Our ambition is for Cerulea to be a world-recognised and trusted partner in clinical trials, playing a pivotal role in translating research discoveries expertly and efficiently from bench to bedside.
We are committed to delivering the best clinical trial experience for participants, clinicians, and sponsors for discoveries that will become therapies on world markets.
Our work and specialist capabilities in trailing advanced therapeutics such as gene and cell therapies, will provide Australians living with vision loss and blindness early access to emerging new treatments.
We also have a remit to partner with Melbourne’s flourishing biotech and medtech ecosystem – providing opportunities for local scientists and inventors to trial new eye treatments and devices in Australia.
Our purpose-built ophthalmic trials unit, located in the Royal Victorian Eye and Ear Hospital, and was built with the support for a $10million investment from Breakthrough Victoria, an independent organisation that manages an innovation investment fund established by the Victorian Government.
We are registered with the Australian Charities and Not-for-Profits Commission and governed by a separate Board which includes representatives from CERA, Breakthrough Victoria and independent directors with expertise in global clinical trials and translational research.
Our revenue is invested back into vision research at CERA, as well as investing in creating a better experience for trial participants, clinicians and sponsors, and into new equipment and services that can be utilized by trial sponsors and clinician researchers, to support investigator-initiated clinical research and fund vital lab-based discovery research.
Working together, we will put new treatments in sight for people living with vision loss and blindness.
About CERA
Our parent company, the Centre for Eye Research Australia, is an independent medical research institute and world leader in ophthalmic research.
CERA is proudly affiliated with the University of Melbourne and Royal Victorian Eye and Ear Hospital.
CERA leads ophthalmic research and teaching within the University’s Department of Surgery and provides post-graduate research opportunities for students in a range of disciplines including ophthalmology, optometry, engineering, materials science and population health.
Learn about CERA
CERA is home to extensive discovery and translational research program aiming to find better ways to diagnose, prevent and treat major eye diseases including age-related macular degeneration, diabetic eye disease, glaucoma and inherited retinal disease.
Our parent company, the Centre for Eye Research Australia, is an independent medical research institute and world leader in ophthalmic research.
CERA is proudly affiliated with the University of Melbourne and Royal Victorian Eye and Ear Hospital.
CERA leads ophthalmic research and teaching within the University’s Department of Surgery and provides post-graduate research opportunities for students in a range of disciplines including ophthalmology, optometry, engineering, materials science and population health.
Learn about CERA
CERA is home to extensive discovery and translational research program aiming to find better ways to diagnose, prevent and treat major eye diseases including age-related macular degeneration, diabetic eye disease, glaucoma and inherited retinal disease.
Our people
From an experienced clinical team to a Board comprising expertise in trial governance and leadership, Cerulea’s team is committed to providing the best experience for participants, clinicians and sponsors.
From an experienced clinical team to a Board comprising expertise in trial governance and leadership, Cerulea’s team is committed to providing the best experience for participants, clinicians and sponsors.
Careers
Find out about opportunities to join the Cerulea Clinical Trials team.
Working at Cerulea
Join a team with deep experience in delivering innovative clinical trials. Learn more about career opportunities at Cerulea Clinical Trials.
Find out about opportunities to join the Cerulea Clinical Trials team.
Working at Cerulea
Join a team with deep experience in delivering innovative clinical trials. Learn more about career opportunities at Cerulea Clinical Trials.